Cologne, 02 July 2020 – The paper, published in the journal Cancers, evaluates and discusses the clinical utility of Tumor mutation burden (TMB) in a 417 patient Non-Small Cell Lung Cancer (NSCLC) cohort. It provides an example of how highly complex biomarkers such as TMB can be implemented into routine laboratory diagnostics using the NEOplus v2 RUO assay.